NordicInfu Care AB Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • NordicInfu Care AB's estimated annual revenue is currently $43.4M per year.(i)
  • NordicInfu Care AB's estimated revenue per employee is $251,000

Employee Data

  • NordicInfu Care AB has 173 Employees.(i)
  • NordicInfu Care AB grew their employee count by 6% last year.

NordicInfu Care AB's People

NameTitleEmail/Phone
1
Head Regulatory, QA and PVReveal Email/Phone
2
Nordic Business Unit & External Affairs DirectorReveal Email/Phone
3
Associate Director, AccountingReveal Email/Phone
4
Quality & Regulatory Affairs Manager MedtechReveal Email/Phone
5
Key Account ManagerReveal Email/Phone
6
Key Account Manager NeurologyReveal Email/Phone
7
Key Account Manager, NeurologyReveal Email/Phone
8
Nordic Customer Experience Manager NeurologyReveal Email/Phone
9
Key Account ManagerReveal Email/Phone
10
Key Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is NordicInfu Care AB?

See www.infucare.com

keywords:N/A

N/A

Total Funding

173

Number of Employees

$43.4M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NordicInfu Care AB News

2019-03-26 - Anders Bodin Fastigheter hyr ut vid Alviks torg

Via två avtal har Anders Bodin hyrt ut drygt 1.100 kvm i sina fastigheter vid Alviks Torg, Stockholm. NordicInfu Care har tecknat ett 6-årigt avtal ...

2018-10-08 - TFS Collaboration with Lobsor Pharmaceuticals AB, on the ...

It is a fully owned subsidiary to Lobsor Holding AB. Lobsor has signed a collaboration agreement with NordicInfu Care for market insights in the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M1732%N/A
#2
$24.8M17329%N/A
#3
$22.8M17330%N/A
#4
$46.6M1732%N/A
#5
$40M173N/AN/A